- Home
- RLYB vs ALGS Comparison
RLYB vs ALGS Comparison
Compare RLYB & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- ALGS
- Stock Information
- Founded
- RLYB 2018
- ALGS 2018
- Country
- RLYB United States
- ALGS United States
- Employees
- RLYB N/A
- ALGS N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- ALGS Health Care
- Exchange
- RLYB Nasdaq
- ALGS Nasdaq
- Market Cap
- RLYB 25.0M
- ALGS 28.8M
- IPO Year
- RLYB 2021
- ALGS 2020
- Fundamental
- Price
- RLYB $0.25
- ALGS $4.68
- Analyst Decision
- RLYB Hold
- ALGS Strong Buy
- Analyst Count
- RLYB 5
- ALGS 1
- Target Price
- RLYB $11.50
- ALGS $70.00
- AVG Volume (30 Days)
- RLYB 194.2K
- ALGS 189.0K
- Earning Date
- RLYB 05-08-2025
- ALGS 05-06-2025
- Dividend Yield
- RLYB N/A
- ALGS N/A
- EPS Growth
- RLYB N/A
- ALGS N/A
- EPS
- RLYB N/A
- ALGS N/A
- Revenue
- RLYB $636,000.00
- ALGS $3,945,000.00
- Revenue This Year
- RLYB N/A
- ALGS $580.86
- Revenue Next Year
- RLYB N/A
- ALGS N/A
- P/E Ratio
- RLYB N/A
- ALGS N/A
- Revenue Growth
- RLYB N/A
- ALGS N/A
- 52 Week Low
- RLYB $0.22
- ALGS $3.76
- 52 Week High
- RLYB $2.00
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- RLYB 22.80
- ALGS 27.34
- Support Level
- RLYB $0.24
- ALGS $4.33
- Resistance Level
- RLYB $0.28
- ALGS $5.67
- Average True Range (ATR)
- RLYB 0.06
- ALGS 0.92
- MACD
- RLYB -0.02
- ALGS 0.24
- Stochastic Oscillator
- RLYB 6.12
- ALGS 18.29
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.